Enliven Therapeutics stock

ELVNNASDAQ

Enliven Therapeutics, Inc., HealthcareISIN US29337E1029

$48.31▼ $2.88 (−5.6%)Closing price of 12 Nov 2026

44Score 44 out of 100, Weak

Turn on early warning

Price and trend

81 / 100

Price history

+138% in one year

The chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.

TrendAbove the 200-day line, momentum normal

Long-term trend

Above the 200-day line: the price is 11% above it.

Trend change

Since January 2026 the 50-day line has been above the 200-day line; the trend has turned up.

Momentum

Normal: the price is neither overheated nor sold off (RSI 67).

Distance to the high

The price is 21% below its 52-week high. Largest decline in 7 years: 98% (June 2020 to April 2022).

Chart figures for advanced users

SMA 50$46.65: Average price of the last 50 trading days, shows the short-term trend.
SMA 200$43.72: Average price of the last 200 trading days, shows the long-term trend.
RSI (14)67: Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
MACDabove the signal line: Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
Support$15.14: The lowest closing price of the last twelve months.
Resistance$61.15: The highest closing price of the last twelve months.

What would $1,000 in Enliven Therapeutics have become?Return triangle for Enliven Therapeutics

Market cap

$3.56B

Div. yield

no dividend

Loss

Loss expected

Fair value

no data

Snapshot

Computed from the data by fixed rules, no AI

Enliven Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $3.56B, is number 89 of 289 companies in its industry on MEQIRI.
MEQIRI Score 44 out of 100 (Weak): rank 465 of 702 in Healthcare, median 53.

In plain words

The numbers on this page in plain words, written by an AI

Strengths

More cash than debtCash $462.62M, financial debt $399K.Stability 69

Weaknesses

Loss-makingLoss of $103.69M over the last 12 months.Fundamentals 17
Negative free cash flowFree cash flow −$70.46M over the last 12 months.Fundamentals 17
Volatile share priceVolatility 78% a year over the last 12 months.Stability 69

44/ 100

Score

Weak

Its standout strengths are momentum and technical analysis, while fundamentals and profitability hold the score back.

Daily figure as of 13 Nov 2026

How the score is calculated

Score overview

Score since yesterday from 45 to 44.

Fundamental quality fluctuates.

Profit consistency0% of years

Cash conversion (free cash flow to earnings, fiscal 2025)not measured

ROIC−24.6%

Positive free cash flow0% of years

How this category is measured

Score history

The full history of up to 20 years comes with MEQIRI Pro.

See plans

Valuation

Valuation signal

not measured

Price

$48.31

Fair value

not computable

Gap to fair value

no data

No fair value can be calculated for this stock, so the signal follows the valuation grade.

Valuation metrics

no data

Fair value (model)

no data

No fair value can be calculated for this stock from the available figures.

Calculate with your own assumptions

Company performance

This shows several years of history with an automatic assessment.

Revenue

9 years

Margins

9 years

Gross margin
Operating margin
Net margin

In fiscal 2025: gross 0%, operating 0%, net 0%.

Debt & balance sheet

latest quarter

no data

45.95

Cash & equivalents

$462.62M

Debt is low; no interest coverage is reported.

Earnings

Next earnings: 2 Mar 2027in 109 days
Last reported: 5 Nov 2026EPS reported −$0.36 (expected −$0.45)above expectations

Analyst estimates

Analysts have raised their 2027 earnings estimate by 8.6% since 15 Oct 2026.

Fiscal 20267 analysts

Earnings per share: −$1.72+6.9%
Revenue: $10K0.0%

Fiscal 20278 analysts

Earnings per share: −$2.09+8.6%
Revenue: $5K0.0%

MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.

InsidersNo buys in the last 6 months, 6 insiders sold

Insiders

Open-market purchases and sales by executives, board members and major holders

All insider purchases

No open-market purchases in the last 6 months. 6 insiders sold, $65.59M in total.

Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.

Hohl BenjaminSale
19 Oct 2026, CHIEF FINANCIAL OFFICER
Shares
6,018
Price
$38.48
Value
$231,546
Collins Helen LouiseSale
19 Oct 2026, CHIEF MEDICAL OFFICER
Shares
5,000
Price
$38.47
Value
$192,342
Garland J. ScottSale
1 Oct 2026, Board
Shares
13,000
Price
$46.67
Value
$606,719

Show 14 more

Hohl BenjaminSale
17 Sept 2026, CHIEF FINANCIAL OFFICER
Shares
6,018
Price
$50.35
Value
$303,003
Collins Helen LouiseSale
17 Sept 2026, CHIEF MEDICAL OFFICER
Shares
5,000
Price
$50.35
Value
$251,754
Hohl BenjaminSale
17 Aug 2026, CHIEF FINANCIAL OFFICER
Shares
6,018
Price
$58.58
Value
$352,551
Collins Helen LouiseSale
17 Aug 2026, CHIEF MEDICAL OFFICER
Shares
5,000
Price
$58.59
Value
$292,931
Derynck Mika KSale
4 Aug 2026, Board
Shares
158,795
Price
$60.21
Value
$9.56M
Hohl BenjaminSale
17 Jul 2026, CHIEF FINANCIAL OFFICER
Shares
6,018
Price
$52.64
Value
$316,780
Collins Helen LouiseSale
17 Jul 2026, CHIEF MEDICAL OFFICER
Shares
5,000
Price
$52.67
Value
$263,373
Kunkel Lori AnneSale
6 Jul 2026, Board
Shares
10,000
Price
$50.49
Value
$504,903
Orbimed Advisors LlcSale
22 Jun 2026, Major holder
Shares
860,123
Price
$45.36
Value
$39.01M
Hohl BenjaminSale
17 Jun 2026, CHIEF FINANCIAL OFFICER
Shares
6,018
Price
$43.80
Value
$263,577
Collins Helen LouiseSale
17 Jun 2026, CHIEF MEDICAL OFFICER
Shares
5,000
Price
$43.80
Value
$219,017
Orbimed Advisors LlcSale
15 Jun 2026, Major holder
Shares
281,408
Price
$45.02
Value
$12.67M
Kunkel Lori AnneSale
5 Jun 2026, Board
Shares
10,000
Price
$34.54
Value
$345,351
Collins Helen LouiseSale
18 May 2026, CHIEF MEDICAL OFFICER
Shares
5,000
Price
$39.79
Value
$198,971

Trade date	Person	Type	Shares	Price	Value	Holding
19 Oct 2026	Hohl BenjaminCHIEF FINANCIAL OFFICER	Sale	6,018	$38.48	$231,546	38,000
19 Oct 2026	Collins Helen LouiseCHIEF MEDICAL OFFICER	Sale	5,000	$38.47	$192,342	25,000
1 Oct 2026	Garland J. ScottBoard	Sale	13,000	$46.67	$606,719	0
17 Sept 2026	Hohl BenjaminCHIEF FINANCIAL OFFICER	Sale	6,018	$50.35	$303,003	38,000
17 Sept 2026	Collins Helen LouiseCHIEF MEDICAL OFFICER	Sale	5,000	$50.35	$251,754	25,000
17 Aug 2026	Hohl BenjaminCHIEF FINANCIAL OFFICER	Sale	6,018	$58.58	$352,551	40,036
17 Aug 2026	Collins Helen LouiseCHIEF MEDICAL OFFICER	Sale	5,000	$58.59	$292,931	25,000
4 Aug 2026	Derynck Mika KBoard	Sale	158,795	$60.21	$9.56M	0
17 Jul 2026	Hohl BenjaminCHIEF FINANCIAL OFFICER	Sale	6,018	$52.64	$316,780	46,054
17 Jul 2026	Collins Helen LouiseCHIEF MEDICAL OFFICER	Sale	5,000	$52.67	$263,373	25,000
6 Jul 2026	Kunkel Lori AnneBoard	Sale	10,000	$50.49	$504,903	41,884
22 Jun 2026	Orbimed Advisors LlcMajor holder	Sale	860,123	$45.36	$39.01M	6,774,507
17 Jun 2026	Hohl BenjaminCHIEF FINANCIAL OFFICER	Sale	6,018	$43.80	$263,577	51,000
17 Jun 2026	Collins Helen LouiseCHIEF MEDICAL OFFICER	Sale	5,000	$43.80	$219,017	25,000
15 Jun 2026	Orbimed Advisors LlcMajor holder	Sale	281,408	$45.02	$12.67M	7,634,630
5 Jun 2026	Kunkel Lori AnneBoard	Sale	10,000	$34.54	$345,351	51,884
18 May 2026	Collins Helen LouiseCHIEF MEDICAL OFFICER	Sale	5,000	$39.79	$198,971	25,000

Show 9 more

Partial trades from one filing are shown in one row, with the average price.

Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.

What happened at Enliven Therapeutics2 events in recent months

What happened at Enliven Therapeutics

The key events of the last six months from our own data. A click takes you to the matching card.

Sector comparisonRank 465 of 702 in Healthcare

Sector comparison

702 rated companies in Healthcare

Rank 465 of 702

465/ 702

This company: 44
Sector median: 53

Categories against the sector medianMedian of 702 companies

Profitability12 (median 38)26 below the median

Growth50 (median 54)4 below the median

Fundamentals17 (median 46)29 below the median

Stability69 (median 67)2 above the median

Capital allocation18 (median 39)21 below the median

Technical analysis81 (median 69)12 above the median

Momentum89 (median 70)19 above the median

The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.

Competitors in Biotechnology

The next larger and next smaller companies by market value

All 289 Biotechnology stocks

ETFs that hold Enliven TherapeuticsHeld by 12 ETFs on Xetra

ETFs that hold Enliven Therapeutics

Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.

ETF	Weight	Cost	Fund size
Harbor Health Care UCITS ETF AccW311	0.96%	0.89%	€11.72M
iShares Nasdaq US Biotechnology UCITS ETF2B70	0.22%	0.35%	€1.25B
Xtrackers Russell 2000 UCITS ETF 1CXRS2	0.10%	0.30%	€2.22B

Show 5 more

State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR	0.10%	0.30%	€4.28B
iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG	0.05%	0.43%	€2.5B
iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG	0.04%	0.10%	€395.74M
L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ	0.04%	0.30%	€185.82M
iShares MSCI World Small Cap UCITS ETFIUSN	0.02%	0.35%	€8.27B

Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).

Data status and sourcesWhen it was calculated, from which sources

Data status and sources

Score: Daily value of 13 Nov 2026, recalculated nightly
Price: Closing price of 12 Nov 2026
Latest annual report: Fiscal year 2025, period end 31 Dec 2025
Source: Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Original filings at the SEC Report a data error

Mandatory disclosures for this rating

Computed on 13 Nov 2026, 03:34 Berlin time; time horizon around 12 months
Rated Weak, published since 7 Nov 2026 (in the score history since 31 Mar 2021)
End-of-day prices, metrics cached for up to 24 hours
Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

Full disclosures, methodology and data sources All ratings of the last 12 months How the score is calculated

Enliven Therapeutics stock

Price and trend

Price history

Snapshot

In plain words

Strengths

Weaknesses

Score overview

Score history

Valuation

Valuation signal

Valuation metrics

Company performance

Revenue

Earnings (net income)

Operating income

Earnings per share

Free cash flow

Operating cash flow

Shares outstanding

Shareholders' equity

Margins

Returns on capital

Cash and debt

Debt & balance sheet

Earnings

Analyst estimates

Insiders

What happened at Enliven Therapeutics

Sector comparison

Categories against the sector medianMedian of 702 companies

Competitors in Biotechnology

ETFs that hold Enliven Therapeutics

Data status and sources

Mandatory disclosures for this rating